Sign in
TerminatedPhase 1/2

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Key facts

Who runs it
AlloVir
Where
Atlanta, Boston, Buffalo, Chapel Hill, Charleston, Cleveland, Duarte, Durham, Gainesville, Houston, Iowa City, Kansas City, Miami, Milwaukee, Nashville, Richmond, Scottsdale, Seattle, and Winston-Salem, United StatesSee the 21 sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
17 people enrolled
Started
21 Mar 2022
Ended
31 Jan 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ALVR106
  • Placebo
Record updated
6 June 2024
Why it stopped
Strategic sponsor decision

Who can take part

Age
17 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Undergone hematopoietic cell transplantation (HCT) ≥21 days or solid organ transplantation (SOT) ≥28 days prior to study treatment administration
  • Detection of at least 1 target virus of interest (ie, RSV, influenza, hMPV, and/or PIV)
  • Diagnosis of Upper or mild Lower Respiratory Tract Infection

Who cannot take part

  • Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose >0.5 mg/kg/day)
  • Infection by novel coronavirus disease 2019 (COVID-19)
  • For HCT patients, evidence of Grade >2 GVHD; and for SOT patients, any history or evidence of GVHD

Where in United States

  • Northside HospitalAtlanta, United States
  • Dana-Farber Cancer InstituteBoston, United States
  • Roswell Park Comprehensive Cancer CenterBuffalo, United States
  • University of North Carolina Lineberger Comprehensive Cancer CenterChapel Hill, United States
  • Medical University of South CarolinaCharleston, United States
  • The Cleveland Clinic FoundationCleveland, United States
  • City of HopeDuarte, United States
  • Duke University Medical CenterDurham, United States
  • University of Florida Division of Hematology & OncologyGainesville, United States
  • Baylor College of MedicineHouston, United States
  • MD AndersonHouston, United States
  • MD Anderson Cancer CenterHouston, United States
  • University of IowaIowa City, United States
  • University of Kansas Cancer CenterKansas City, United States
  • University of Miami - Sylvester Cancer CenterMiami, United States
  • Froedtert Hospital and the Medical College of WisconsinMilwaukee, United States
  • Vanderbilt University Cancer CenterNashville, United States
  • Virginia Commonwealth UniversityRichmond, United States
  • Scottsdale Healthcare Hospitals DBA HonorHealthScottsdale, United States
  • Fred Hutchinson Cancer Research CenterSeattle, United States
  • Wake ForestWinston-Salem, United States

About the trial

What the trial wants to find out

A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT) and solid organ transplant (SOT).

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo, visually identical to ALVR106

  • ALVR106Existing treatment, for comparison

    ALVR106, visually identical to placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Record updated
6 June 2024